Does COVID-19 predispose patients to type 1 diabetes mellitus?
The novel coronavirus disease (COVID-19) has emerged as a global pandemic. This was a prospective, case-control study conducted in Izmir, Turkey. The aim of this study was to assess the relationship between COVID-19 and new-onset T1DM. We included pediatric patients (aged 6 mo–18 yr) with new-onset...
Gespeichert in:
Veröffentlicht in: | Clinical Pediatric Endocrinology 2022, Vol.31(1), pp.33-37 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 37 |
---|---|
container_issue | 1 |
container_start_page | 33 |
container_title | Clinical Pediatric Endocrinology |
container_volume | 31 |
creator | Ata, Aysun Jalilova, Arzu Kırkgöz, Tarık Işıklar, Hafize Demir, Günay Altınok, Yasemin Atik Özkan, Behzat Zeytinlioğlu, Ayşin Darcan, Şükran Özen, Samim Gökşen, Damla |
description | The novel coronavirus disease (COVID-19) has emerged as a global pandemic. This was a prospective, case-control study conducted in Izmir, Turkey. The aim of this study was to assess the relationship between COVID-19 and new-onset T1DM. We included pediatric patients (aged 6 mo–18 yr) with new-onset type-1 diabetes mellitus (T1DM) diagnosed during the COVID-19 pandemic, between April 2020 and January 2021. Polymerase chain reaction was used to diagnose COVID-19 after hospital admission. An enzyme-linked immunoassay for IgM and IgG against SARS-CoV-2 was performed after the diagnosis was confirmed. In the control group, the blood antibody test was conducted as close as possible to the time of the T1DM patient referral. A total of 118 participants were included in the study, comprising 57 (48%) patients with new-onset T1DM and 61 (52%) healthy controls. Of the 57 patients, 36 (63.2%) presented with DKA, 17 (29.7%) with diabetic ketosis, and four (7%) incidentally. The SARS-CoV-2 antibody test was positive in five (8.7%) patients with T1DM and six (10%) controls. The rate of positivity did not differ between the two groups (p = 0.901). It was not possible to demonstrate a clear association between SARS-CoV-2 infection and new-onset T1DM. Whether SARS-CoV-2 increases susceptibility to diabetes by triggering islet cell autoimmunity and affects the timing of overt diabetes in patients with existing autoimmunity should be studied in large cohorts. |
doi_str_mv | 10.1297/cpe.2021-0050 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8713063</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2618514221</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5090-51b4025997c10200bacac3fc739f90fb896c9feec8479139809d7197cca2a38b3</originalsourceid><addsrcrecordid>eNpVkE1LAzEQhoMoWqtHr7JHL1tnku5HLoq0fkGhF_UasumsRrbdNUmF_ntTW6teksA8vPPmYewMYYBcFpemowEHjilABnush2JYpIXIyn3WA4llmhVCHrFj798BuIQcDtmRyOIb8rzHrsYt-WQ0fXkcpyiTztHM-q71lHQ6WFoEn4Q2CauOEkxmVlcUIj-nprFh6a9P2EGtG0-n27vPnu9un0YP6WR6_zi6maQmAwlphtUQeCZlYTAuhkobbURtYrVaQl2VMjeyJjLlsJAoZAlyVmCkjeZalJXos6tNbres5jQzsZjTjeqcnWu3Uq226v9kYd_Ua_upygIF5CIGXGwDXPuxJB_U3HoTv6EX1C694jmWGQ45x4imG9S41ntH9W4Nglo7V9G5WjtXa-eRP__bbUf_SI7AaAO8-6BfaQdoF6xp6DtOoML1sYv9nb5pp2ghvgCc4pOM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2618514221</pqid></control><display><type>article</type><title>Does COVID-19 predispose patients to type 1 diabetes mellitus?</title><source>J-STAGE Free</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Ata, Aysun ; Jalilova, Arzu ; Kırkgöz, Tarık ; Işıklar, Hafize ; Demir, Günay ; Altınok, Yasemin Atik ; Özkan, Behzat ; Zeytinlioğlu, Ayşin ; Darcan, Şükran ; Özen, Samim ; Gökşen, Damla</creator><creatorcontrib>Ata, Aysun ; Jalilova, Arzu ; Kırkgöz, Tarık ; Işıklar, Hafize ; Demir, Günay ; Altınok, Yasemin Atik ; Özkan, Behzat ; Zeytinlioğlu, Ayşin ; Darcan, Şükran ; Özen, Samim ; Gökşen, Damla</creatorcontrib><description>The novel coronavirus disease (COVID-19) has emerged as a global pandemic. This was a prospective, case-control study conducted in Izmir, Turkey. The aim of this study was to assess the relationship between COVID-19 and new-onset T1DM. We included pediatric patients (aged 6 mo–18 yr) with new-onset type-1 diabetes mellitus (T1DM) diagnosed during the COVID-19 pandemic, between April 2020 and January 2021. Polymerase chain reaction was used to diagnose COVID-19 after hospital admission. An enzyme-linked immunoassay for IgM and IgG against SARS-CoV-2 was performed after the diagnosis was confirmed. In the control group, the blood antibody test was conducted as close as possible to the time of the T1DM patient referral. A total of 118 participants were included in the study, comprising 57 (48%) patients with new-onset T1DM and 61 (52%) healthy controls. Of the 57 patients, 36 (63.2%) presented with DKA, 17 (29.7%) with diabetic ketosis, and four (7%) incidentally. The SARS-CoV-2 antibody test was positive in five (8.7%) patients with T1DM and six (10%) controls. The rate of positivity did not differ between the two groups (p = 0.901). It was not possible to demonstrate a clear association between SARS-CoV-2 infection and new-onset T1DM. Whether SARS-CoV-2 increases susceptibility to diabetes by triggering islet cell autoimmunity and affects the timing of overt diabetes in patients with existing autoimmunity should be studied in large cohorts.</description><identifier>ISSN: 0918-5739</identifier><identifier>EISSN: 1347-7358</identifier><identifier>DOI: 10.1297/cpe.2021-0050</identifier><identifier>PMID: 35002066</identifier><language>eng</language><publisher>Japan: The Japanese Society for Pediatric Endocrinology</publisher><subject>children ; COVID-19 ; diabetes mellitus ; Original ; type-1</subject><ispartof>Clinical Pediatric Endocrinology, 2022, Vol.31(1), pp.33-37</ispartof><rights>2022 by The Japanese Society for Pediatric Endocrinology</rights><rights>2022©The Japanese Society for Pediatric Endocrinology.</rights><rights>2022©The Japanese Society for Pediatric Endocrinology 2022</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5090-51b4025997c10200bacac3fc739f90fb896c9feec8479139809d7197cca2a38b3</citedby><cites>FETCH-LOGICAL-c5090-51b4025997c10200bacac3fc739f90fb896c9feec8479139809d7197cca2a38b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8713063/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8713063/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,1877,4010,27900,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35002066$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ata, Aysun</creatorcontrib><creatorcontrib>Jalilova, Arzu</creatorcontrib><creatorcontrib>Kırkgöz, Tarık</creatorcontrib><creatorcontrib>Işıklar, Hafize</creatorcontrib><creatorcontrib>Demir, Günay</creatorcontrib><creatorcontrib>Altınok, Yasemin Atik</creatorcontrib><creatorcontrib>Özkan, Behzat</creatorcontrib><creatorcontrib>Zeytinlioğlu, Ayşin</creatorcontrib><creatorcontrib>Darcan, Şükran</creatorcontrib><creatorcontrib>Özen, Samim</creatorcontrib><creatorcontrib>Gökşen, Damla</creatorcontrib><title>Does COVID-19 predispose patients to type 1 diabetes mellitus?</title><title>Clinical Pediatric Endocrinology</title><addtitle>Clinical Pediatric Endocrinology</addtitle><description>The novel coronavirus disease (COVID-19) has emerged as a global pandemic. This was a prospective, case-control study conducted in Izmir, Turkey. The aim of this study was to assess the relationship between COVID-19 and new-onset T1DM. We included pediatric patients (aged 6 mo–18 yr) with new-onset type-1 diabetes mellitus (T1DM) diagnosed during the COVID-19 pandemic, between April 2020 and January 2021. Polymerase chain reaction was used to diagnose COVID-19 after hospital admission. An enzyme-linked immunoassay for IgM and IgG against SARS-CoV-2 was performed after the diagnosis was confirmed. In the control group, the blood antibody test was conducted as close as possible to the time of the T1DM patient referral. A total of 118 participants were included in the study, comprising 57 (48%) patients with new-onset T1DM and 61 (52%) healthy controls. Of the 57 patients, 36 (63.2%) presented with DKA, 17 (29.7%) with diabetic ketosis, and four (7%) incidentally. The SARS-CoV-2 antibody test was positive in five (8.7%) patients with T1DM and six (10%) controls. The rate of positivity did not differ between the two groups (p = 0.901). It was not possible to demonstrate a clear association between SARS-CoV-2 infection and new-onset T1DM. Whether SARS-CoV-2 increases susceptibility to diabetes by triggering islet cell autoimmunity and affects the timing of overt diabetes in patients with existing autoimmunity should be studied in large cohorts.</description><subject>children</subject><subject>COVID-19</subject><subject>diabetes mellitus</subject><subject>Original</subject><subject>type-1</subject><issn>0918-5739</issn><issn>1347-7358</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNpVkE1LAzEQhoMoWqtHr7JHL1tnku5HLoq0fkGhF_UasumsRrbdNUmF_ntTW6teksA8vPPmYewMYYBcFpemowEHjilABnush2JYpIXIyn3WA4llmhVCHrFj798BuIQcDtmRyOIb8rzHrsYt-WQ0fXkcpyiTztHM-q71lHQ6WFoEn4Q2CauOEkxmVlcUIj-nprFh6a9P2EGtG0-n27vPnu9un0YP6WR6_zi6maQmAwlphtUQeCZlYTAuhkobbURtYrVaQl2VMjeyJjLlsJAoZAlyVmCkjeZalJXos6tNbres5jQzsZjTjeqcnWu3Uq226v9kYd_Ua_upygIF5CIGXGwDXPuxJB_U3HoTv6EX1C694jmWGQ45x4imG9S41ntH9W4Nglo7V9G5WjtXa-eRP__bbUf_SI7AaAO8-6BfaQdoF6xp6DtOoML1sYv9nb5pp2ghvgCc4pOM</recordid><startdate>2022</startdate><enddate>2022</enddate><creator>Ata, Aysun</creator><creator>Jalilova, Arzu</creator><creator>Kırkgöz, Tarık</creator><creator>Işıklar, Hafize</creator><creator>Demir, Günay</creator><creator>Altınok, Yasemin Atik</creator><creator>Özkan, Behzat</creator><creator>Zeytinlioğlu, Ayşin</creator><creator>Darcan, Şükran</creator><creator>Özen, Samim</creator><creator>Gökşen, Damla</creator><general>The Japanese Society for Pediatric Endocrinology</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>2022</creationdate><title>Does COVID-19 predispose patients to type 1 diabetes mellitus?</title><author>Ata, Aysun ; Jalilova, Arzu ; Kırkgöz, Tarık ; Işıklar, Hafize ; Demir, Günay ; Altınok, Yasemin Atik ; Özkan, Behzat ; Zeytinlioğlu, Ayşin ; Darcan, Şükran ; Özen, Samim ; Gökşen, Damla</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5090-51b4025997c10200bacac3fc739f90fb896c9feec8479139809d7197cca2a38b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>children</topic><topic>COVID-19</topic><topic>diabetes mellitus</topic><topic>Original</topic><topic>type-1</topic><toplevel>online_resources</toplevel><creatorcontrib>Ata, Aysun</creatorcontrib><creatorcontrib>Jalilova, Arzu</creatorcontrib><creatorcontrib>Kırkgöz, Tarık</creatorcontrib><creatorcontrib>Işıklar, Hafize</creatorcontrib><creatorcontrib>Demir, Günay</creatorcontrib><creatorcontrib>Altınok, Yasemin Atik</creatorcontrib><creatorcontrib>Özkan, Behzat</creatorcontrib><creatorcontrib>Zeytinlioğlu, Ayşin</creatorcontrib><creatorcontrib>Darcan, Şükran</creatorcontrib><creatorcontrib>Özen, Samim</creatorcontrib><creatorcontrib>Gökşen, Damla</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical Pediatric Endocrinology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ata, Aysun</au><au>Jalilova, Arzu</au><au>Kırkgöz, Tarık</au><au>Işıklar, Hafize</au><au>Demir, Günay</au><au>Altınok, Yasemin Atik</au><au>Özkan, Behzat</au><au>Zeytinlioğlu, Ayşin</au><au>Darcan, Şükran</au><au>Özen, Samim</au><au>Gökşen, Damla</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Does COVID-19 predispose patients to type 1 diabetes mellitus?</atitle><jtitle>Clinical Pediatric Endocrinology</jtitle><addtitle>Clinical Pediatric Endocrinology</addtitle><date>2022</date><risdate>2022</risdate><volume>31</volume><issue>1</issue><spage>33</spage><epage>37</epage><pages>33-37</pages><artnum>2021-0050</artnum><issn>0918-5739</issn><eissn>1347-7358</eissn><abstract>The novel coronavirus disease (COVID-19) has emerged as a global pandemic. This was a prospective, case-control study conducted in Izmir, Turkey. The aim of this study was to assess the relationship between COVID-19 and new-onset T1DM. We included pediatric patients (aged 6 mo–18 yr) with new-onset type-1 diabetes mellitus (T1DM) diagnosed during the COVID-19 pandemic, between April 2020 and January 2021. Polymerase chain reaction was used to diagnose COVID-19 after hospital admission. An enzyme-linked immunoassay for IgM and IgG against SARS-CoV-2 was performed after the diagnosis was confirmed. In the control group, the blood antibody test was conducted as close as possible to the time of the T1DM patient referral. A total of 118 participants were included in the study, comprising 57 (48%) patients with new-onset T1DM and 61 (52%) healthy controls. Of the 57 patients, 36 (63.2%) presented with DKA, 17 (29.7%) with diabetic ketosis, and four (7%) incidentally. The SARS-CoV-2 antibody test was positive in five (8.7%) patients with T1DM and six (10%) controls. The rate of positivity did not differ between the two groups (p = 0.901). It was not possible to demonstrate a clear association between SARS-CoV-2 infection and new-onset T1DM. Whether SARS-CoV-2 increases susceptibility to diabetes by triggering islet cell autoimmunity and affects the timing of overt diabetes in patients with existing autoimmunity should be studied in large cohorts.</abstract><cop>Japan</cop><pub>The Japanese Society for Pediatric Endocrinology</pub><pmid>35002066</pmid><doi>10.1297/cpe.2021-0050</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0918-5739 |
ispartof | Clinical Pediatric Endocrinology, 2022, Vol.31(1), pp.33-37 |
issn | 0918-5739 1347-7358 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8713063 |
source | J-STAGE Free; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access |
subjects | children COVID-19 diabetes mellitus Original type-1 |
title | Does COVID-19 predispose patients to type 1 diabetes mellitus? |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T16%3A33%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Does%20COVID-19%20predispose%20patients%20to%20type%201%20diabetes%20mellitus?&rft.jtitle=Clinical%20Pediatric%20Endocrinology&rft.au=Ata,%20Aysun&rft.date=2022&rft.volume=31&rft.issue=1&rft.spage=33&rft.epage=37&rft.pages=33-37&rft.artnum=2021-0050&rft.issn=0918-5739&rft.eissn=1347-7358&rft_id=info:doi/10.1297/cpe.2021-0050&rft_dat=%3Cproquest_pubme%3E2618514221%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2618514221&rft_id=info:pmid/35002066&rfr_iscdi=true |